Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan

Abstract

• A longitudinal analysis of 15 months pre-intervention and 15 months post-intervention for the Arkansas State Employee Benefits Division (EBD) found that the addition of omeprazole OTC to coverage and adjustment of the community pharmacy dispensing fee to account for fewer prescriptions filled (with a 42-day vs. 30-day supply) were associated with a decrease of $4,207,350 in proton pump inhibitor (PPI) drug cost or $3,365,880 over 12 months ($2.20 PMPM). What is already known about this subject

Cost minimization of cardiovascular disease (CVD) drugs in primary healthcare centers in Bandung, Indonesia

“…In 2014, amlodipine was included in DU70% and DU90% and this drug has the highest price per unit among other CVD drugs. The same findings were stated by Johnson [20] and Valluri [21] , the drug cost and procurement method influenced the drug utilities in community healthcare.…”